Sobi Set To Grow Hematology Franchise With $1.7bn CTI Biopharma Buy
Deal Prices Target Company At Big Premium
Executive Summary
Sobi plans to capitalize on the complimentary expertise at CTI Biopharma to together boost sales of the latter firm’s myelofibrosis drug Vonjo and enhance the Swedish pharma firm’s overall growth.